Literature DB >> 26494783

Solution-Phase Crosstalk and Regulatory Interactions Between Multipotent Adult Progenitor Cells and Peripheral Blood Mononuclear Cells.

Gregory G Burrows1, Wouter Van't Hof2, Ashok P Reddy3, Phillip A Wilmarth3, Larry L David3, Amy Raber4, Annelies Bogaerts5, Lien Timmerman5, Jef Pinxteren5, Valerie D Roobrouck5, Robert J Deans6, Richard T Maziarz7.   

Abstract

UNLABELLED: Multipotent adult progenitor cells (MAPCs) are adult adherent stromal stem cells currently being assessed in clinical trials for acute graft versus host disease with demonstrated immunomodulatory capabilities and the potential to ameliorate detrimental autoimmune and inflammation-related processes. Anti-CD3/anti-CD28 (3/28) activation of T cells within the peripheral blood mononuclear cell (PBMC) compartment was performed in the presence or absence of MAPCs. Liquid chromatography-coupled tandem mass spectrometry was used to characterize the differential secretion of proteins, and transcriptional profiling was used to monitor mRNA expression changes in both cell populations. Overall, 239 secreted and/or ectodomain-shed proteins were detected in the secretomes of PBMCs and MAPCs. In addition, 3/28 activation of PBMCs induced differential expression of 2,925 genes, and 22% of these transcripts were differentially expressed on exposure to MAPCs in Transwell. MAPCs exposed to 3/28-activated PBMCs showed differential expression of 1,247 MAPC genes. Crosstalk was demonstrated by reciprocal transcriptional regulation. Secretome proteins and transcriptional signatures were used to predict molecular activities by which MAPCs could dampen local and systemic inflammatory responses. These data support the hypothesis that MAPCs block PBMC proliferation via cell cycle arrest coupled to metabolic stress in the form of tryptophan depletion, resulting in GCN2 kinase activation, downstream signaling, and inhibition of cyclin D1 translation. These data also provide a plausible explanation for the immune privilege reported with administration of donor MAPCs. Although most components of the major histocompatibility complex class II antigen presentation pathway were markedly transcriptionally upregulated, cell surface expression of human leukocyte antigen-DR is minimal on MAPCs exposed to 3/28-activated PBMCs. SIGNIFICANCE: This study documents experiments quantifying solution-phase crosstalk between multipotent adult progenitor cells (MAPCs) and peripheral blood mononuclear cells. The secretome and transcriptional changes quantified suggest mechanisms by which MAPCs are hypothesized to provide both local and systemic immunoregulation of inflammation. The potential impact of these studies includes development of a robust experimental framework to be used for preclinical evaluation of the specific mechanisms by which beneficial effects are obtained after treatment of patients with MAPCs. ©AlphaMed Press.

Entities:  

Keywords:  Anti-CD3/anti-CD28-activated PBMC; Cell cycle arrest; Immune tolerance; Multipotent adult progenitor cell; mRNA gene array

Mesh:

Year:  2015        PMID: 26494783      PMCID: PMC4675500          DOI: 10.5966/sctm.2014-0225

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  74 in total

1.  Human multipotent adult progenitor cells transcriptionally regulate fucosyltransferase VII.

Authors:  Gregory G Burrows; Richard T Maziarz; Karen Hunady; Nicholas Lehman; Amy Raber; Robert J Deans; Wouter Van't Hof
Journal:  Cytotherapy       Date:  2013-10-29       Impact factor: 5.414

2.  Transplantation of cryopreserved human bone marrow-derived multipotent adult progenitor cells for neonatal hypoxic-ischemic injury: targeting the hippocampus.

Authors:  Takao Yasuhara; Noriyuki Matsukawa; Guolong Yu; Lin Xu; Robert W Mays; Jim Kovach; Robert Deans; David C Hess; James E Carroll; Cesar V Borlongan
Journal:  Rev Neurosci       Date:  2006       Impact factor: 4.353

3.  Global Characterization and Genomic Stability of Human MultiStem, A Multipotent Adult Progenitor Cell.

Authors:  Sherry Boozer; Nicholas Lehman; Uma Lakshmipathy; Brad Love; Amy Raber; Anirban Maitra; Robert Deans; Mahendra S Rao; Anthony E Ting
Journal:  J Stem Cells       Date:  2009

4.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Babak Baban; Heather P Harding; Yuhong Zhang; David Ron; Andrew L Mellor
Journal:  Immunity       Date:  2005-05       Impact factor: 31.745

Review 5.  Tumour microenvironment: laminin 332 in squamous-cell carcinoma.

Authors:  M Peter Marinkovich
Journal:  Nat Rev Cancer       Date:  2007-05       Impact factor: 60.716

6.  Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation.

Authors:  Roland Meisel; Andree Zibert; Maurice Laryea; Ulrich Göbel; Walter Däubener; Dagmar Dilloo
Journal:  Blood       Date:  2004-03-04       Impact factor: 22.113

7.  Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases.

Authors:  Takahisa Takino; Naohiko Koshikawa; Hisashi Miyamori; Motohiro Tanaka; Takuma Sasaki; Yasunori Okada; Motoharu Seiki; Hiroshi Sato
Journal:  Oncogene       Date:  2003-07-24       Impact factor: 9.867

8.  Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism.

Authors:  Farida Djouad; Louis-Marie Charbonnier; Carine Bouffi; Pascale Louis-Plence; Claire Bony; Florence Apparailly; Céline Cantos; Christian Jorgensen; Danièle Noël
Journal:  Stem Cells       Date:  2007-05-17       Impact factor: 6.277

Review 9.  Mesenchymal stem cells and autoimmune diseases.

Authors:  Francesco Dazzi; Mauro Krampera
Journal:  Best Pract Res Clin Haematol       Date:  2011-02-23       Impact factor: 3.020

10.  Furin is the major proprotein convertase required for KISS1-to-Kisspeptin processing.

Authors:  Sitaram Harihar; Keke M Pounds; Tomoo Iwakuma; Nabil G Seidah; Danny R Welch
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

View more
  3 in total

1.  Multipotent adult progenitor cells improve the hematopoietic function in myelodysplasia.

Authors:  Valerie D Roobrouck; Esther Wolfs; Michel Delforge; Dorien Broekaert; Soumen Chakraborty; Kathleen Sels; Thomas Vanwelden; Bryan Holvoet; Larissa Lhoest; Satish Khurana; Shubham Pandey; Chloé Hoornaert; Peter Ponsaerts; Tom Struys; Nancy Boeckx; Peter Vandenberghe; Christophe M Deroose; Catherine M Verfaillie
Journal:  Cytotherapy       Date:  2017-06       Impact factor: 5.414

2.  Multipotent adult progenitor cells induce regulatory T cells and promote their suppressive phenotype via TGFβ and monocyte-dependent mechanisms.

Authors:  Alice Valentin-Torres; Cora Day; Jennifer M Taggart; Nicholas Williams; Samantha R Stubblefield; Valerie D Roobrouck; Jelle Beyens; Anthony E Ting
Journal:  Sci Rep       Date:  2021-06-30       Impact factor: 4.379

3.  Anti-Inflammatory Action of Heterogeneous Nuclear Ribonucleoprotein A2/B1 in Patients with Autoimmune Endocrine Disorders.

Authors:  Antonina Coppola; Patrizia Cancemi; Laura Tomasello; Valentina Guarnotta; Maria Pitrone; Valentina Failla; Salvatore Cillino; Salvatore Feo; Giuseppe Pizzolanti; Carla Giordano
Journal:  J Clin Med       Date:  2019-12-19       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.